Literature DB >> 20709417

Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers.

Christine Haie-Meder1, Renaud Mazeron, Nicolas Magné.   

Abstract

PET-CT plays an increasing role in the diagnosis and treatment of gynaecological cancers. In cervix cancer, whilst MRI remains the best imaging technique for initial primary tumor staging, PET-CT has been showed to be a highly sensitive method to determine lymph node status, except in patients with early-stage cervical cancer where PET-CT cannot replace surgical exploration of pelvic lymph nodes. In patients with advanced cervical cancer, PET-CT has the potential of showing lymph node metastasis not only within the pelvis, but also outside the pelvis, more particularly in the para-aortic area. PET-CT has also been described as a useful tool in 3-D-based adaptative brachytherapy. In endometrial cancer, the issues are different, as the recent decade has seen a therapeutic decrease in early-stage disease, especially in postoperative radiation therapy, whilst more advanced disease have been approached with more aggressive treatments, integrating chemotherapy and external beam radiotherapy. Lymph node status is also an important issue and PET-Scan may replace lymph node surgical procedure particularly in obese patients. Copyright 2010 European Society for Therapeutic Radiology and Oncology and European Association of Nuclear Medicine. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20709417     DOI: 10.1016/j.radonc.2010.07.010

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  13 in total

Review 1.  Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT : part 1.

Authors:  Kerstin A Brocker; Celine D Alt; Michael Eichbaum; Christof Sohn; Hans-Ulrich Kauczor; Peter Hallscheidt
Journal:  Strahlenther Onkol       Date:  2011-09-23       Impact factor: 3.621

2.  The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer.

Authors:  LingLing Pan; JingYi Cheng; Min Zhou; ZhiFeng Yao; YingJian Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-20       Impact factor: 4.553

3.  Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy.

Authors:  Cyrus Chargari; Renaud Mazeron; Ariane Dunant; Sébastien Gouy; Claire Petit; Pierre Maroun; Catherine Uzan; Pierre Annede; Enrica Bentivegna; Corinne Balleyguier; Catherine Genestie; Patricia Pautier; Alexandra Leary; Catherine Lhomme; Eric Deutsch; Philippe Morice; Christine Haie-Meder
Journal:  Clin Exp Metastasis       Date:  2016-08-16       Impact factor: 5.150

4.  Positron-emission tomography for locally advanced cervical cancer: a survey assessing Canadian practice patterns and access.

Authors:  R Banerjee; G Dundas; C Doll
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

Review 5.  Brachytherapy in cancer cervix: Time to move ahead from point A?

Authors:  Anurita Srivastava; Niloy Ranjan Datta
Journal:  World J Clin Oncol       Date:  2014-10-10

6.  Why are we still in the 1950s regarding management of cancer of uterine cervix ?

Authors:  K R Das
Journal:  J Med Phys       Date:  2012-10

7.  Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes.

Authors:  Nathalie Rochet; Rachel S Kahn; Andrzej Niemierko; Thomas F Delaney; Anthony H Russell
Journal:  Radiat Oncol       Date:  2013-10-14       Impact factor: 3.481

8.  The role of [(18)F]FDG-PET/CT in staging and treatment planning for volumetric modulated Rapidarc radiotherapy in cervical cancer: experience of the European Institute of Oncology, Milan, Italy.

Authors:  Roberta Lazzari; Agnese Cecconi; Barbara A Jereczek-Fossa; Laura Lavinia Travaini; Veronica Dell' Acqua; Federica Cattani; Stefania Rizzo; Cristiana Fodor; Fabio Landoni; Roberto Orecchia
Journal:  Ecancermedicalscience       Date:  2014-03-05

Review 9.  The role of PET-CT in radiotherapy planning of solid tumours.

Authors:  Stasa Jelercic; Mirjana Rajer
Journal:  Radiol Oncol       Date:  2015-03-03       Impact factor: 2.991

10.  Impact of 18F-FDG PET/CT on target volume delineation in recurrent or residual gynaecologic carcinoma.

Authors:  Hansjörg Vees; Nathalie Casanova; Thomas Zilli; Hestia Imperiano; Osman Ratib; Youri Popowski; Hui Wang; Habib Zaidi; Raymond Miralbell
Journal:  Radiat Oncol       Date:  2012-10-22       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.